10-Q · May 15, 2026
MiNK Therapeutics reported a net loss of $1.7 million for Q1 2026, with an EPS of -0.56, beating consensus estimates of -0.68. The company has maintained a cash balance of $9.5 million but faces ongoing operating losses…
Earnings analysis · 10-Q
INKT earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
MiNK reported Q2 2026 EPS of negative $0.62, missing the negative $0.60 consensus estimate, while net loss improved to $3.1 million from $4.2 million year over year. Cash declined to $8.8 million, and the filing…
Read full summary
MiNK reported Q2 2026 EPS of negative $0.62, missing the negative $0.60 consensus estimate, while net loss improved to $3.1 million from $4.2 million year over year. Cash declined to $8.8 million, and the filing provides no formal quantitative revenue or EPS guidance. Preliminary agenT-797 Day 28 observations were positive, but the small patient sample and lack of additional data until early 2027 leave substantial clinical and financing uncertainty.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.62
What stood out
-
Year-over-year loss improved
Q2 2026 EPS was a loss of $0.62, compared with a loss of $1.06 in Q2 2025 and a loss of $0.57 in Q1 2026; EPS missed the $0.60 loss consensus estimate by $0.02.
-
Net loss narrowed year over year
Net loss improved to $3.1 million from $4.2 million in the prior-year quarter, a $1.1 million improvement.
-
Early clinical observations positive
Preliminary Day 28 observations for agenT-797 were positive, with additional data expected in early 2027.
-
No material control weaknesses reported
Management concluded disclosure controls were effective as of June 30, 2026, and reported no changes during the quarter that materially affected internal control over financial reporting.
What to watch
-
Cash balance continues to decline
Cash declined to $8.8 million, increasing financing and liquidity risk for the development program.
-
Clinical evidence remains preliminary
The positive agenT-797 Day 28 observations are preliminary and based on a small number of patients; additional data are not expected until early 2027.
-
No new risk disclosures, existing risks remain
The filing states there were no material changes to the risk factors in the 2025 Form 10-K, but also warns that legal proceedings could adversely affect business, results, financial condition or cash flows.
Management's outlook
No formal quantitative revenue or EPS guidance was provided; additional agenT-797 trial data are expected in early 2027.
Earlier filings 4
10-K · March 31, 2026
MiNK Therapeutics positions itself as a platform company developing allogeneic, off-the-shelf iNKT cell therapies (lead candidate agenT-797) across oncology, critical pulmonary immune failure and GvHD, while also…
10-Q · August 14, 2025
MiNK Therapeutics reported no revenue for Q2 2025 with a significant net loss of $4.24 million, growing from a loss of $2.70 million in the prior year. Operating expenses increased notably, driven by research and…
10-Q · May 15, 2025
MiNK Therapeutics reported improved operating and per-share results in Q1 2025 with net loss narrowing to $(2,766,697) (EPS $(0.70)) versus $(3,813,295) (EPS $(1.10)) in Q1 2024. The improvement was driven by a sharp…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.